CALCIUM GLUCONATE 10 % INJECTION B.P.

Land: Israël

Taal: Engels

Bron: Ministry of Health

Werkstoffen:

CALCIUM GLUCONATE

Beschikbaar vanaf:

LAPIDOT MEDICAL IMPORT AND MARKETING LTD

ATC-code:

A12AA03

farmaceutische vorm:

SOLUTION FOR INJECTION

Samenstelling:

CALCIUM GLUCONATE 0.94 G / 10 ML

Toedieningsweg:

I.V

Prescription-type:

Required

Geproduceerd door:

B.BRAUN MELSUNGEN AG, GERMANY

Therapeutische categorie:

CALCIUM GLUCONATE

Therapeutisch gebied:

CALCIUM GLUCONATE

therapeutische indicaties:

Treatment of acute symptomatic hypocalcaemia.

Autorisatie datum:

2023-05-31

Productkenmerken

570/12394629/0213
schwarz
Format = 210 x 297 mm (A4)
2 Seiten
Lätus
IL___570
570/12394629/0213
Calcium Gluconate 10% Injection B.P.
MP – GIF
Standort Berlin
G 080624
B|BRAUN
Calcium is insoluble in adipose tissue and may therefore cause
infiltra-
tion and subsequent abscess formation, tissue induration and necrosis.
After perivascular or superficial IM injection local irritation,
possibly fol-
lowed by skin ablation or tissue necrosis, may occur, see also section
“UNDESIRABLE EFFECTS”. Extravasation must be avoided; the
injection site
should be monitored carefully.
High Vitamin D intake should be avoided.
PREGNANCY AND LACTATION
_Pregnancy:_
Calcium passes across the placental barrier and its concentration in
fetal
blood is higher than in maternal blood.
Calcium gluconate injections should be used during pregnancy only if
considered to be essential by the physician. The administered dose
should
be carefully calculated, and the serum calcium level regularly
evaluated in
order to avoid hypercalcaemia, which may be deleterious for the
foetus.
_Lactation:_
Calcium is excreted in breast milk This should be borne in mind when
administering calcium to women who are breast-feeding their infants.
INTERACTIONS
The effects of _digoxin_ and other _cardiac glycosides_ may be
potentiated
by calcium, which may result in serious toxicity. Therefore,
intravenous
administration of calcium preparations to patients under therapy with
cardiac glycosides is contraindicated. The only exception may be that
IV calcium administration is imperative for treatment of severe hypoc-
alcaemia symptoms putting the patient at immediate vital risk, if
safer
therapeutic alternatives are not available and calcium administration
via
the oral route is not possible (see also sections
“CONTRAINDICATIONS” and
“SPECIAL WARNINGS …”).
Co-administration of calcium and _epinephrine_ may lead to cardiac ar-
rhythmia.
Calcium and _magnesium_ mutually antagonise their effects.
Calcium may antagonise the effect of _ calcium antagonists_ (calcium